First-in-class molecules T-168 and T-621 reduce oxidative stress, inflammation and enhance autophagy

→ T-168 is in clinical phase 2 for neurodegenerative diseases (Parkinson’s disease, ALS)

→ T-168 has been selected for the Neuro-SysMed Parkinson's disease SLEIPNIR trial with funding from Cure Parkinson’s, the Norwegian Parkinson’s Research Fund and the Norwegian Parkinson’s Association

→ T-621 is in IND enabling studies

Broad indication expansion opportunities in neurodegenerative, metabolic, muscle, and aging-related diseases